CD274 and non-small cell lung carcinoma: The latest NCCN guidelines (2018) suggested a cutoff value for PD‐L1 expression of a least 50% for the use of PD1/PDL1 antibody therapy as the first‐line treatment for NSCLC.21 However, different studies have indicated the existence of some controversy regarding the cutoff PD‐L1 expression value for a patient to be considered PD‐L1‐positive.22, 23 Our meta‐analysis showed a positive correlation for OS and PFS with PD‐L1 expression.